Table 1.
Species | Peak retention time (min) | Peak activity | Mascot results matching the exact mass | Exact mass from MS data | Exact mass calculated from Mascot data | Toxin class | Dose required for full inhibition |
---|---|---|---|---|---|---|---|
B. asper | 18.9–20.0 | Anticoagulation | PA2H2_BOTAS | 13,714.565 | 13,715 | PLA2 | PN |
20.1–21.0 | Anticoagulation | PA2HA_BOTAS | 13,912.465 | 13,897 | PLA2 | PN | |
20.1–21.0 | Anticoagulation | PA2H3_BOTAS | 13,765.581 | 13,766 | PLA2 | PN | |
21.0–21.5 | Anticoagulation | PA2B3_BOTAS | 13,957.533 | 13,957 | PLA2 | PN | |
21.0–21.5 | Anticoagulation | PA2A2_BOTAS | – | 14,194 | PLA2 | PN | |
21.0–21.5 | Anticoagulation | VM2_BOTAS | – | 53,564 | SVMP | NOI | |
20.8–22.4 | Procoagulation | VSPL_BOTAS | – | 28,019 | SVSP | PN | |
20.8–22.4 | Procoagulation | VM1B1_BOTAS | – | 45,936 | SVMP | PN | |
21.2–22.4 | Procoagulation | SLA_BOTAS | 7084 | CTL | PN | ||
B. jararaca | 20.5–21.1 | Anticoagulation | – | – | – | – | NOI |
20.2–21.7 | Procoagulation | VSPA_BOTJA | – | 25,584 | SVSP | PN | |
20.2–21.7 | Procoagulation | VSP1_BOTJA | – | 25,742 | SVSP | PN | |
20.2–21.7 | Procoagulation | VSP2_BOTJA | – | 27,894 | SVSP | PN | |
20.2–21.7 | Procoagulation | VSP12_BOTJA | – | 27,988 | SVSP | PN | |
20.2–21.7 | Procoagulation | VSP14_BOTJA | – | 27,843 | SVSP | PN | |
20.2–21.7 | Procoagulation | VSP20_BOTJA | – | 27,815 | SVSP | PN | |
C. rhodostoma | 19.3–20.5 | Anticoagulation | PA2BD_CALRH | 13,665.085 | 13,665 | PLA2 | NOI |
19.3–20.5 | Anticoagulation | PA2AB_CALRH | – | 14,352 | PLA2 | NOI | |
19.3–20.5 | Anticoagulation | VSPF1_CALRH | – | 26,570 | SVSP | NOI | |
19.3–20.5 | Anticoagulation | SLEA_CALRH | – | 15,962 | CTL | NOI | |
19.3–20.5 | Anticoagulation | SLEB_CALRH | – | 15,190 | CTL | NOI | |
19.3–21.6 | Procoagulation | VSPF2_CALRH | – | 29,145 | SVSP | PN | |
19.9–21.6 | Procoagulation | SLYA_CALRH | – | 15,796 | CTL | PN | |
19.9–21.6 | Procoagulation | SLYB_CALRH | – | 16,770 | CTL | PN | |
D. acutus | 20.4–20.9 | Anticoagulation | PA2A_DEIAC | – | 14,820 | PLA2 | 4 μmol/L varespladib |
20.4–20.9 | Anticoagulation | SL_DEIAC | – | 18,332 | CTL | 4 μmol/L varespladib | |
21.4–21.7 | Anticoagulation | – | – | – | – | NOI | |
21.0–22.7 | Procoagulation | VSP1_DEIAC | – | 29,480 | SVSP | PN | |
21.0–22.7 | Procoagulation | VSPA_DEIAC | – | 26,132 | SVSP | PN | |
21.4–22.7 | Procoagulation | SLCB_DEIAC | – | 17,133 | CTL | PN | |
21.4–22.7 | Procoagulation | VM1AC_DEIAC | – | 47,690 | SVMP | PN | |
21.4–22.7 | Procoagulation | VM11_DEIAC | – | 47,845 | SVMP | PN | |
21.4–22.7 | Procoagulation | VM1H5_DEIAC | – | 46,518 | SVMP | PN | |
21.4–22.7 | Procoagulation | VM3AK_DEIAC | – | 69,752 | SVMP | PN | |
22.7–23.4 | Procoagulation | VM3A2_DEIAC | – | 27,151 | SVMP | 20 μmol/L varespladib/4 μmol/L marimastat | |
22.7–23.4 | Procoagulation | VM3AH_DEIAC | – | 70,721 | SVMP | 20 μmol/L varespladib/4 μmol/L marimastat |
Peak retention times are adapted from Figure 1, Figure 2, Figure 3, Figure 4; PLA2 = phospholipase A2; SVMP = snake venom metalloproteinase; SVSP = snake venom serine protease; CTL=C-type lectin; PN = partly neutralised at 20 μmol/L inhibitor concentrations; NOI = no observed inhibition; ‒ Not applicable.